In gene therapy, immunogenicity isn't just a hurdle, it's a make-or-break factor!
Whether you are in the early or late stages of development, reliable data specific to your vector is essential to ensure relevance in your vector’s safety profile assessment.
Assessing the presence of anti-AAV antibodies and their neutralizing and toxicity capacity can also be essential. That´s where our AAV Safety Trifecta comes in!